McIlroy, Graham
Lax, Siân
Gaskell, Charlotte
Jackson, Aimee
Rhodes, Malcolm
Seale, Tania
Fox, Sonia
Hopkins, Lousie
Okosun, Jessica
Barrington, Sally F.
Ringshausen, Ingo
Ramsay, Alan G.
Calaminici, Maria
Linton, Kim
Bishton, Mark
Article History
Received: 14 February 2024
Accepted: 12 March 2024
First Online: 25 March 2024
Declarations
:
: The trial will be performed in accordance with the recommendations guiding physicians in biomedical research involving human subjects, adopted by the 18th World Medical Association General Assembly, Helsinki, Finland and stated in the respective participating countries laws governing human research, and Good Clinical Practice. The protocol has been approved by the UK (London - Fulham Research Ethics Committee on 22-Jun-2023). Competent Authority approval was granted in the UK by the Medicines and Healthcare Products Regulatory Agency (MHRA) on 01-Jun-2023; the current protocol (v3.0) was approved on 14th February 2024.
: All patients provide written informed consent to participate.
: Not applicable.
: GM– None. SL– None. CG– None. AJ– None. MR– None. TS– None. SF– None. LH– None. JO– Research support: AstraZeneca and BeiGene. Honoraria: AstraZeneca, Eisai, Janssen. Advisory boards: Eisai, BeiGene; Incyte. SFB– None. IR– NoneAGR– Research support to Institution: Bristol-Myers SquibbMC– NoneKL– Research support: Takeda, Roche, Genmab, Abbvie. Honoraria: Abbvie, Celgene, Roche. Advisory Boards: Abbvie, Roche, Genmab, Kite/Gilead, Beigene, BMS. Travel, accommodation: Celgene. MB– Honoraria: Roche, Takeda, Celltrion, Kite/Gilead. Consulting or Advisory Role: Incyte, Roche, Lilly, AbbVie. Travel, accommodations, expenses: Roche.